var title_f2_29_2512="Trendelenburg test";
var content_f2_29_2512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trendelenburg test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normally, the pelvis stays level when a patient stands on one leg. When standing on the affected leg, the pelvis tilts downward toward the unaffected side (as pictured in the abnormal patient above) because of gluteal muscle weakness on the affected side (left side in abnormal patient above).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2512=[""].join("\n");
var outline_f2_29_2512=null;
var title_f2_29_2513="Straight needle holder";
var content_f2_29_2513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Straight needle-holder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 279px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Needle-gripping surfaces are pictured in the inset.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2513=[""].join("\n");
var outline_f2_29_2513=null;
var title_f2_29_2514="Doppler pentalogy of Cantrell";
var content_f2_29_2514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color Doppler picture of a 10 week fetus with pentalogy of Cantrell",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2514=[""].join("\n");
var outline_f2_29_2514=null;
var title_f2_29_2515="Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL)";
var content_f2_29_2515=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Management of atypical squamous cells (ASC-US and ASC-H) and low grade cervical squamous intraepithelial lesions (LSIL) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/29/2515/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2515/contributors\" id=\"au4124\">",
"       Anne Kathryn Goodman, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2515/contributors\" id=\"au4484\">",
"       Christine H Holschneider, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/29/2515/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2515/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/29/2515/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2515/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/29/2515?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The cervix and vagina are lined by cells called squamous cells (",
"     <a class=\"graphic graphic_picture graphicRef77157 \" href=\"UTD.htm?42/63/44019\">",
"      picture 1",
"     </a>",
"     ). Atypical squamous cells (ASC) is the name given to squamous cells on a Pap smear (also called cervical cytology) that do not have a normal appearance but are not clearly precancerous. Low grade squamous intraepithelial lesions (LSIL, also called low grade cervical intraepithelial neoplasia) refers to cells that appear slightly abnormal.",
"    </p>",
"    <p>",
"     Women who have ASC or LSIL on a Pap smear require further testing because some women with these findings have a precancerous lesion of the cervix.",
"    </p>",
"    <p>",
"     This topic review discusses the management of women with ASC and LSIL. The management of women with high grade squamous intraepithelial lesions (HSIL) and atypical glandular cells (AGC) are discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      \"Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ATYPICAL SQUAMOUS CELLS (ASC)",
"     </span>",
"    </p>",
"    <p>",
"     ASC is subdivided into atypical squamous cells of undetermined significance (ASC-US) and atypical squamous cells, cannot rule out a high grade lesion (ASC-H). The risk of a high-grade precancerous lesion in women with ASC-US is 15 percent and for those with ASC-H, the risk is 38 percent [",
"     <a class=\"abstract\" href=\"UTD.htm?2/29/2515/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Cervical cancer screening is recommended starting at age 21 years. Management of abnormal Pap smears performed in women age 20 or younger is discussed below. (See",
"     <a class=\"local\" href=\"#H17556778\">",
"      'Adolescents'",
"     </a>",
"     below.) Management of abnormal Pap smears in women who are pregnant is also discussed below. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Pregnant women'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Atypical squamous cells of undetermined significance (ASC-US)",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are three options for evaluation of a single ASC-US result.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Perform HPV testing. This is the preferred follow up for ASC-US. HPV testing is often done at the same time as the Pap smear. This is convenient because the woman does not have to return for a second visit. HPV testing is described in detail in a separate topic review (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"        \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"       </a>",
"       ).",
"       <br/>",
"       <br/>",
"       Women who test positive for HPV types that are high risk for cervical cancer should have colposcopy because they are at greater risk of having an underlying precancerous lesion.",
"       <br/>",
"       <br/>",
"       Women who test negative for HPV are not likely to have cervical precancer. These women should have a repeat Pap smear in one year. In most cases, the ASC-US resolves during this time.",
"      </li>",
"      <li>",
"       Repeat the Pap smear in six months. If this test is normal, it is repeated once more after another six months until there have been two normal tests in a row; the woman can then return to routine screening. If the woman has a second ASC-US result or a more severe abnormality develops, colposcopy is recommended. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Colposcopy'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Have colposcopy. (See",
"       <a class=\"local\" href=\"#H6\">",
"        'Colposcopy'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Atypical squamous cells, cannot rule out a high grade lesion (ASC-H)",
"     </span>",
"     &nbsp;&mdash;&nbsp;ASC-H is more likely than ASC-US to be caused by a precancerous change. This finding requires further evaluation with colposcopy (see",
"     <a class=\"local\" href=\"#H6\">",
"      'Colposcopy'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      LOW-GRADE SQUAMOUS LESION (LSIL)",
"     </span>",
"    </p>",
"    <p>",
"     LSIL is usually caused by mild cellular changes. Further testing with colposcopy and cervical biopsy is almost always recommended for women with LSIL because 12 to 16 percent of women with LSIL have a precancerous lesion [",
"     <a class=\"abstract\" href=\"UTD.htm?2/29/2515/abstract/2,3\">",
"      2,3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The management of women with LSIL depends upon what is seen with colposcopy and biopsy (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Management after colposcopy'",
"     </a>",
"     below); most clinicians will delay biopsy until after delivery in pregnant women (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Pregnant women'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Adolescents and are evaluated somewhat differently (see",
"     <a class=\"local\" href=\"#H17556778\">",
"      'Adolescents'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      COLPOSCOPY",
"     </span>",
"    </p>",
"    <p>",
"     Colposcopy is an office procedure that allows a clinician to closely examine the cervix. It is commonly performed after an abnormal Pap smear. Colposcopy is performed similar to a pelvic examination, while the woman lies on an exam table. A speculum is used to view the cervix, and the viewing device (called a colposcope) remains outside the woman's body (",
"     <a class=\"graphic graphic_picture graphicRef77157 \" href=\"UTD.htm?42/63/44019\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The colposcope magnifies the appearance of the cervix. This allows the clinician to better see the location and size of any abnormalities, and also to see any changes in the capillaries (small blood vessels) on the surface of the cervix.",
"    </p>",
"    <p>",
"     During colposcopy, a small piece of the abnormal area can be removed (biopsied). Anesthesia (numbing medicine) is not needed because the biopsy causes only mild discomfort or cramping.",
"    </p>",
"    <p>",
"     Some women also need to have a biopsy of the inner cervix during colposcopy; this is called endocervical curettage (ECC). Endocervix refers to the inner cervix and curettage means scraping. Pregnant women should not have ECC because it may disturb the pregnancy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Management after colposcopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most women who have a colposcopy have a biopsy of any abnormal-appearing areas. The biopsy samples are sent to a pathologist who determines if there is any evidence of precancerous changes, termed cervical intraepithelial neoplasia (CIN). These changes are categorized as being mild (CIN 1) or moderate to severe (CIN 2 or 3).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        CIN 1 biopsy in women with Pap smear results that were ASC-US, ASC-H or LSIL cytology",
"       </strong>",
"       &ndash; Follow-up is recommended with either HPV testing at 12 months or a Pap smear at 6 and 12 months. The reason for this recommendation is that CIN 1 is a minor abnormality that usually goes away over time without treatment. Waiting and repeating testing allows time for the abnormality to resolve and also enables the healthcare provider to identify the few situations in which the abnormality has become more severe. Repeat colposcopy is recommended if the results of the follow-up Pap smear are ASC or greater or if the HPV test is positive. Women with two consecutive negative repeat cytology results or a negative HPV test can resume routine screening.",
"      </li>",
"      <li>",
"       <strong>",
"        CIN 1 biopsy in women with Pap smear results that were high-grade SIL (HSIL) or atypical glandular cells-not otherwise specified",
"       </strong>",
"       &ndash; Follow-up can be one of three options: (1) Pap smear and colposcopy every six months for a year; (2) re-review of both Pap smear and biopsy results by a pathologist; or (3) a procedure to remove a larger piece of tissue from the cervix (cone biopsy or loop electrosurgical excision procedure [called LEEP, loop, or LLETZ]).",
"      </li>",
"      <li>",
"       <strong>",
"        CIN 2 or 3",
"       </strong>",
"       &mdash; CIN 2 or 3 is usually treated by removing or destroying the abnormal area (using a cone biopsy, LEEP, laser, or freezing procedure [cryotherapy]). The reason for this recommendation is that moderate to severe precancerous abnormalities (CIN 2 or 3) are unlikely to resolve over time without treatment and may progress to cancer if left untreated over a period of years. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"        \"Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)\"",
"       </a>",
"       .) However, in some cases, treatment can be delayed in adolescents or pregnant women (see",
"       <a class=\"local\" href=\"#H17556778\">",
"        'Adolescents'",
"       </a>",
"       below and",
"       <a class=\"local\" href=\"#H13\">",
"        'Pregnant women'",
"       </a>",
"       below).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SPECIAL CIRCUMSTANCES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Pregnant women",
"     </span>",
"     &nbsp;&mdash;&nbsp;The evaluation and management of pregnant women is different from non-pregnant women because of the risk that trauma to the cervix could lead to preterm labor or delivery.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Atypical squamous cells of undetermined significance (ASC-US)",
"       </strong>",
"       &mdash; Pregnant women with ASC-US are managed in the same manner as other women with ASC-US.",
"      </li>",
"      <li>",
"       <strong>",
"        Atypical squamous cells, cannot rule out a high grade lesion (ASC-H)",
"       </strong>",
"       &mdash; Pregnant women with ASC-H are managed in the same manner as other women with ASC-H.",
"      </li>",
"      <li>",
"       <strong>",
"        Low-grade squamous intraepithelial lesion (LSIL)",
"       </strong>",
"       &mdash; For pregnant women with LSIL, the preferred approach is colposcopy. An alternative is to defer colposcopy until six weeks postpartum.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17556778\">",
"     <span class=\"h2\">",
"      Adolescents",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cervical cancer screening is recommended starting at age 21 years. If a Pap smear is performed in a women age 20 or less and the result is ASC-US or LSIL, the Pap smear should be repeated in 12 months.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3705190\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3705148\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Basic content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3705156\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/44/17092?source=see_link\">",
"      Patient information: Management of high grade cervical squamous intraepithelial lesions (HSIL) and glandular abnormalities (AGC) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14227?source=see_link\">",
"      Patient information: Treatment of precancerous cells of the cervix (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=see_link\">",
"      Cervical adenocarcinoma in situ",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6826?source=see_link\">",
"      Cervical cancer in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/25/9624?source=see_link\">",
"      Cervical cytology: Evaluation of atypical and malignant glandular cells",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=see_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=see_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information [",
"     <a class=\"abstract\" href=\"UTD.htm?2/29/2515/abstract/2,4,5\">",
"      2,4,5",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society for Colposcopy and Cervical Pathology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.asccp.org/\">",
"      www.asccp.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Social Health Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ashastd.org/\">",
"      file://www.ashastd.org/",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/29/2515?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2515/abstract/1\">",
"      Castle PE, Fetterman B, Thomas Cox J, et al. The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer. Obstet Gynecol 2010; 116:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2515/abstract/2\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2515/abstract/3\">",
"      Cox JT, Schiffman M, Solomon D, ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2515/abstract/4\">",
"      Safaeian M, Solomon D, Wacholder S, et al. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol 2007; 109:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2515/abstract/5\">",
"      Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 2007; 197:340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_29_2515=[""].join("\n");
var outline_f2_29_2515=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ATYPICAL SQUAMOUS CELLS (ASC)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           LOW-GRADE SQUAMOUS LESION (LSIL)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           COLPOSCOPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SPECIAL CIRCUMSTANCES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/63/44019\" title=\"picture 1\">",
"           Normal cervix PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_29_2516="Methylnaltrexone: Drug information";
var content_f2_29_2516=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylnaltrexone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/59/14260?source=see_link\">",
"    see \"Methylnaltrexone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6028565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Relistor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6860881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Relistor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6045443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Opioid Antagonist, Peripherally-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6253863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Opioid-induced constipation:",
"     </b>",
"     SubQ: Dosing is according to body weight: Administer 1 dose every other day as needed; maximum: 1 dose/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;38 kg: 0.15 mg/kg (round dose up to nearest 0.1 mL of volume)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     38 to &lt;62 kg: 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     62-114 kg: 12 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;114 kg: 0.15 mg/kg (round dose up to nearest 0.1 mL of volume)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6044679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6044680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate renal impairment: No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     End-stage renal impairment (dialysis-dependent): Has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6044681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment: Has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6044674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relistor&reg;: 8 mg/0.4 mL (0.4 mL); 12 mg/0.6 mL (0.6 mL) [contains edetate calcium disodium; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Relistor&reg;: 12 mg/0.6 mL (0.6 mL) [contains edetate calcium disodium; vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6044183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6044671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Administer subcutaneously into upper arm, abdomen, or thigh. Rotate injection site. Do not use tender, bruised, red, or hard areas.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6044184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of opioid-induced constipation in patients with advanced illness receiving palliative care with inadequate response to conventional laxative regimens",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6044161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methylnaltrexone may be confused with naltrexone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6044651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Gastrointestinal: Abdominal pain (29%), flatulence (13%), nausea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hyperhidrosis (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal cramps, body temperature increased, GI perforation, muscle spasm, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6044185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known or suspected mechanical bowel obstruction",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to methylnaltrexone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6044647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diarrhea: Discontinue treatment for severe or persistent diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intestinal perforation: Gastrointestinal perforation of the colon, duodenum, and stomach has been reported (rarely) in patients with advanced illnesses associated with impaired structural integrity of the GI wall (eg, cancer, Ogilvie&rsquo;s syndrome, peptic ulcer). Use caution in patients with known or history of GI tract lesions; discontinue therapy if persistent, severe, or worsening abdominal symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended for severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Has not been studied in patients with end-stage renal impairment requiring dialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Peritoneal catheters: Use has not been studied in patients with peritoneal catheters.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Use beyond 4 months has not been studied. Discontinue methylnaltrexone if opioids are discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F6044656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6044655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6044643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6044644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6044646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Relistor Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg/0.6 mL (7): $454.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Relistor Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/0.4 mL (0.4 mL): $64.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg/0.6 mL (0.6 mL): $64.97",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Relistor (AR, AT, AU, BE, BR, CN, CZ, DE, DK, EE, FR, GB, GR, HN, IE, IT, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6044661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An opioid receptor antagonist which blocks opioid binding at the mu receptor, methylnaltrexone is a quaternary derivative of naltrexone with restricted ability to cross the blood-brain barrier. It therefore functions as a peripheral acting opioid antagonist, including actions on the gastrointestinal tract to inhibit opioid-induced decreased gastrointestinal motility and delay in gastrointestinal transit time, thereby decreasing opioid-induced constipation. Does not affect opioid analgesic effects or induce opioid withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6044659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Usually within 30-60 minutes (in responding patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: SubQ: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : ~1.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 11% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Metabolized to methyl-6-naltrexol isomers, methylnaltrexone sulfate, and other minor metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: ~8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: SubQ: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~50%, primarily as unchanged drug); feces (&lt;50%, primarily as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Portenoy RK, Thomas J, Moehl Boatwright ML, et al, &ldquo;Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients With Advanced Illness: A Double-Blind Randomized, Parallel Group, Dose-Ranging Study,&rdquo;",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 2008, 35(5):458-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2516/abstract-text/18440447/pubmed\" id=\"18440447\" target=\"_blank\">",
"        18440447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas J, &ldquo;Opioid-Induced Bowel Dysfunction,&rdquo;",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 2008, 35(1):103-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2516/abstract-text/17981003/pubmed\" id=\"17981003\" target=\"_blank\">",
"        17981003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thomas J, Karver S, Cooney GA, et al, &ldquo;Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(22):2332-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2516/abstract-text/18509120/pubmed\" id=\"18509120\" target=\"_blank\">",
"        18509120",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yuan CS, &ldquo;Methylnaltrexone Mechanisms of Action and Effects on Opioid Bowel Dysfunction and Other Opioid Adverse Effects,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(6):984-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2516/abstract-text/17504835/pubmed\" id=\"17504835\" target=\"_blank\">",
"        17504835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9444 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-124.240.187.80-4AC29DC90F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2516=[""].join("\n");
var outline_f2_29_2516=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6028565\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860881\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6045443\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6253863\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044679\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044680\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044681\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044674\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044183\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044671\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044184\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044161\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044651\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044185\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044647\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044656\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044655\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044643\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044644\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044646\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321828\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875350\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044661\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6044659\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9444|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/59/14260?source=related_link\">",
"      Methylnaltrexone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_29_2517="Pulmonary embolism";
var content_f2_29_2517=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pulmonary embolism (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/29/2517/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2517/contributors\" id=\"au2656\">",
"       B Taylor Thompson, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2517/contributors\" id=\"au1888\">",
"       Charles A Hales, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/29/2517/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2517/contributors\" id=\"se4218\">",
"       Jess Mandel, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/29/2517/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2517/contributors\" id=\"de8916\">",
"       Geraldine Finlay, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/29/2517?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PULMONARY EMBOLISM OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Pulmonary embolism (PE) occurs when a blood clot dislodges from a vein, travels through the veins of the body, and lodges in the lung. Most blood clots (thrombi) originally form in one of the deep veins of the legs, thighs, or pelvis; this condition is known as deep vein thrombosis (DVT). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The clot or clots block the blood flow to parts of the lung, preventing oxygen from reaching the brain and body. Pulmonary emboli are uncommon, but can be deadly if not identified and treated promptly. In the United States, it is estimated that over 50,000 people die every year as a result of a PE. Recognizing and treating a PE quickly can reduce the risk of serious complications and death.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PULMONARY EMBOLISM RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of factors that increase a person's risk of developing PE.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Inherited thrombophilia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inherited thrombophilia refers to a genetic problem that causes the blood to clot more easily than normal. Various factors in the blood clotting process may be involved, depending on the type of genetic problem present.",
"    </p>",
"    <p>",
"     An inherited thrombophilia, such as deficiencies of antithrombin, protein C, or protein S, is frequently present in people with a venous blood clot (ie, thrombus) who are less than 50 years of age. Other factors, such as factor V Leiden or the prothrombin gene mutation, increase the risk of venous thrombosis in all age groups. However, venous blood clots are infrequent before adolescence.",
"    </p>",
"    <p>",
"     If a person is found to have a PE and there is no known medical condition or recent surgery that caused the PE, it is possible that an inherited condition is the cause. This is especially true in people who have more than one PE or if a family member has also experienced a PE. In these cases, testing for an inherited thrombophilia is often recommended (see",
"     <a class=\"local\" href=\"#H14\">",
"      'Determining the cause'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Elevated clotting factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Having an increased level of one or more factors involved in blood clotting, such as factor VIII, increases the risk of a blood clot.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Medical conditions or medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some medical conditions and medications increase a person's risk of developing a blood clot:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pregnancy",
"      </li>",
"      <li>",
"       Obesity",
"      </li>",
"      <li>",
"       Smoking",
"      </li>",
"      <li>",
"       Cancer",
"      </li>",
"      <li>",
"       Heart failure",
"      </li>",
"      <li>",
"       Previous DVT or PE",
"      </li>",
"      <li>",
"       Increased age",
"      </li>",
"      <li>",
"       Kidney problems, such as nephrotic syndrome (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"        \"Patient information: The nephrotic syndrome (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Certain medications (eg, birth control pills, hormone replacement therapy, tamoxifen, thalidomide, erythropoietin). The risk of a blood clot is further increased in people who use one of these medications and smoke or are overweight.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Surgery and related conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgical procedures, especially those involving the hip, pelvis, or knee, increase a person's risk of developing a blood clot. During the recovery period, this risk often continues because the person is less active. Inactivity during long trips can also increase a person's risk of developing a blood clot. Precautions to reduce the risk of blood clots are discussed below (see",
"     <a class=\"local\" href=\"#H24\">",
"      'Special precautions with pulmonary embolism'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Acquired thrombophilia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some types of thrombophilia are not inherited, but can increase a person's risk of developing a blood clot:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Certain disorders of the blood, such as polycythemia vera or essential thrombocythemia",
"      </li>",
"      <li>",
"       Antiphospholipid antibodies (antibodies in the blood that can affect the clotting process) (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"        \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      PULMONARY EMBOLISM SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The signs and symptoms of PE can vary from one person to another. Common signs and symptoms of pulmonary embolism include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Shortness of breath or needing to breathe rapidly",
"      </li>",
"      <li>",
"       Sharp, knife-like chest pain while taking a deep breath",
"      </li>",
"      <li>",
"       Coughing or coughing up blood",
"      </li>",
"      <li>",
"       A rapid heart rate",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      PULMONARY EMBOLISM DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If a person's history, symptoms, and physical exam suggest a PE, tests are needed to confirm the diagnosis. Tests to diagnose PE include",
"     <span class=\"nowrap\">",
"      ventilation/perfusion",
"     </span>",
"     lung scanning, spiral computed tomography (CT), and pulmonary angiography. Some patients with a suspected PE will also undergo testing to determine if DVT exists, which is described in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .) If a DVT is diagnosed, further testing to determine if a PE is present may not be necessary because both conditions are treated in the same way.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      D-dimer",
"     </span>",
"     &nbsp;&mdash;&nbsp;D-dimer is a substance in the blood that is often increased in people with PE. D-dimer levels are abnormal in 95 percent of patients with PE; a person with a normal D-dimer level is unlikely to have a PE. If the D-dimer test is negative and the patient is thought to have a low risk of PE based upon their signs and symptoms, PE is unlikely and further testing may not be needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Spiral computed tomography",
"     </span>",
"     &nbsp;&mdash;&nbsp;Spiral CT scanning uses a combination of x-rays and computers to take detailed pictures of the inside of the body. The patient lies inside a tube-like structure; x-rays are taken after the injection of an intravenous dye, which highlights the vessels in the lung (CT angiography) or the leg veins (CT venography). Spiral CT is the study of choice in medical centers that have experience performing and interpreting the test.",
"    </p>",
"    <p>",
"     However, spiral CT may not be suitable for patients with poor kidney function and patients who are unable to have a CT for other reasons (eg, an allergy to contrast dye). These patients usually need an alternate test (eg,",
"     <span class=\"nowrap\">",
"      ventilation/perfusion",
"     </span>",
"     lung scan) or special treatment to reduce the risk of an allergic reaction before CT angiography.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Ventilation/perfusion lung scanning",
"     </span>",
"     &nbsp;&mdash;&nbsp;A",
"     <span class=\"nowrap\">",
"      ventilation/perfusion",
"     </span>",
"     lung scan, sometimes called a",
"     <span class=\"nowrap\">",
"      V/Q",
"     </span>",
"     scan, is commonly used to diagnose patients with a suspected PE. During this test, the patient inhales a small amount of a radioactive substance. A radioactive substance is also injected into the bloodstream. A machine is used to examine how these radioactive substances are distributed within the lungs. If a person has a PE, the scanner can detect the area of lung in which the blood flow has been blocked by the blood clot.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Pulmonary angiography",
"     </span>",
"     &nbsp;&mdash;&nbsp;There have been significant improvements in non-invasive tests for PE. However, some patients still require a more invasive test, called pulmonary angiography, to confirm or exclude PE with certainty. Angiography is the \"gold standard\" test to diagnose PE.",
"    </p>",
"    <p>",
"     Pulmonary angiography is performed by inserting a catheter through a vein in the groin area (the femoral vein). The catheter is guided into a branch of the pulmonary artery. Dye is injected through the catheter, highlighting the blood vessels in the lung on x-ray.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Determining the cause",
"     </span>",
"     &nbsp;&mdash;&nbsp;After determining that a PE is present, the clinician will want to know what caused it. In many cases, there are obvious risk factors such as recent surgery or immobility (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Acquired thrombophilia'",
"     </a>",
"     above). In other cases, the person will be tested for inherited thrombophilia (see",
"     <a class=\"local\" href=\"#H3\">",
"      'Inherited thrombophilia'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     Persons with an acquired or inherited abnormality may require additional treatment or preventative measures to reduce the risk of future blood clots. Some experts recommend that the family members of a person with an inherited thrombophilia be screened for the inherited condition if this information would impact their care, although this issue is controversial.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      PULMONARY EMBOLISM TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatments for PE help to prevent a new or enlarging blood clot and reduce the risk of complications related to the clot while the body's own enzymes dissolve the clot. The primary treatment for venous thrombosis is anticoagulation. Other treatments include thrombolytic therapy and placing a \"clot filter\" in one of the major blood vessels (the inferior vena cava).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Anticoagulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulants are medications that are commonly called blood thinners. The medication does not actually thin the blood, but rather prevents new blood clots from forming. Patients with venous thrombosis are usually treated first with an injectable anticoagulant. There are several anticoagulants available, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Unfractionated heparin",
"      </li>",
"      <li>",
"       Low molecular weight heparin",
"       <span class=\"nowrap\">",
"        (enoxaparin/Lovenox&reg;,",
"       </span>",
"       <span class=\"nowrap\">",
"        dalteparin/Fragmin&reg;,",
"       </span>",
"       or",
"       <span class=\"nowrap\">",
"        tinzaparin/Inohep&reg;)",
"       </span>",
"      </li>",
"      <li>",
"       Fondaparinux (Arixtra&reg;)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When two treatment choices are similarly effective, the choice of anticoagulant usually depends upon the healthcare provider's preference, the patient's medical condition and preference, and cost considerations.",
"    </p>",
"    <p>",
"     All of the anticoagulants can be injected into the skin by the patient, a family member, or a home health nurse. This allows a person to be treated at home. Heparin, low molecular weight heparin, or fondaparinux is usually continued for at least five days, along with another medication called warfarin (Coumadin&reg;). Warfarin is a pill that is taken by mouth. After approximately five days, the heparin, low molecular weight heparin, or fondaparinux are discontinued while the warfarin is continued for at least three months.",
"    </p>",
"    <p>",
"     Less commonly, the patient does not take warfarin but takes a daily injection of low molecular weight heparin or fondaparinux for the entire treatment period. Low molecular weight heparin is much more expensive than warfarin, but does not need to be monitored with blood tests.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Duration of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment with an anticoagulant is recommended for a",
"     <strong>",
"      minimum",
"     </strong>",
"     of three months.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       In patients with a reversible risk factor, such as bed rest, the clinician often treats the patient for at least three months or until the risk factor is resolved.",
"      </li>",
"      <li>",
"       Patients with a first episode of a spontaneous or unprovoked venous thrombosis are treated for a",
"       <strong>",
"        minimum",
"       </strong>",
"       of three months. After three months and on a regular basis thereafter, the patient should meet with their healthcare provider to discuss the risks (bleeding) versus the benefits (decreased risk of another clot) of continued treatment. For patients who do NOT have an increased risk of bleeding and can continue anticoagulant monitoring, many experts recommend continuing warfarin indefinitely.",
"      </li>",
"      <li>",
"       Some patients with a first DVT or PE will need anticoagulation indefinitely, especially those with certain risk factors (hereditary thrombophilia or antiphospholipid antibody syndrome).",
"      </li>",
"      <li>",
"       Most experts recommend continuing anticoagulation indefinitely for people with two or more episodes of venous thrombosis or if a risk factor is permanent (eg, a mechanical heart valve).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Thrombolytic therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, a clinician will recommend giving a medicine into a vein to dissolve the blood clot(s). This is called thrombolytic therapy. This therapy is more commonly used in patients who have serious complications related to PE or DVT and in patients with large blood clots in the leg or lung who are at low risk of serious bleeding as a side effect of the thrombolytic therapy. The best chance of responding to thrombolytic therapy is when there is a short time between the diagnosis of",
"     <span class=\"nowrap\">",
"      DVT/PE",
"     </span>",
"     and the start of treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Inferior vena cava filter",
"     </span>",
"     &nbsp;&mdash;&nbsp;An inferior vena cava (IVC) filter is a device that blocks the circulation of clots in the bloodstream. It is placed in the inferior vena cava (the large vein leading from the lower body to the heart) with a catheter that is inserted into a vein in the groin and threaded through the blood vessels. An IVC filter is often recommended in patients with PE who cannot use anticoagulants because of recent surgery, a stroke caused by bleeding, or significant bleeding in another area of the body. IVC filters can be used along with surgical procedures to remove blood clots.",
"    </p>",
"    <p>",
"     An IVC filter is also recommended in some patients who develop recurrent PE despite anticoagulation. It may also be recommended for patients whose lung problems makes them susceptible to life-threatening complications if another PE were to occur.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Embolectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Embolectomy is the medical term for removal of PE from the lung. It may be performed using catheters (similar to those used for pulmonary angiography) or with a surgical procedure that is similar to open heart surgery. This procedure may be considered if a person is in serious condition as a result of the PE (eg, persistent low blood pressure due to PE). In this situation, thrombolytic therapy is usually attempted first. If thrombolysis fails or is not an option, embolectomy may be attempted.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      PULMONARY EMBOLISM PREVENTION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Surgical patients",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain high-risk patients undergoing surgery (especially bone or joint surgery and cancer surgery) may be given anticoagulants to decrease the risk of developing a blood clot. Anticoagulants may also be given to women at high risk for venous thrombosis during and after pregnancy.",
"    </p>",
"    <p>",
"     In surgical patients with a moderate to low risk of blood clots, other preventive measures may be used. For example, some surgical patients are fitted with inflatable compression devices that are worn around the legs during and immediately after surgery. The devices periodically fill with air and apply gentle pressure to improve circulation and help prevent clots.",
"    </p>",
"    <p>",
"     Graduated compression stockings may also be recommended; these stockings should be custom fitted to apply pressure to the lower legs, with the greatest pressure at the ankle. The pressure should gradually decrease up to the knee. For all patients, walking as soon as possible after surgery can decrease the risk of a blood clot.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Extended travel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prolonged travel appears to confer a 2- to 4-fold increase in risk of developing a deep vein thrombosis or pulmonary embolism [",
"     <a class=\"abstract\" href=\"UTD.htm?2/29/2517/abstract/1\">",
"      1",
"     </a>",
"     ]. There are a few tips that may be of benefit during extended travel (",
"     <a class=\"graphic graphic_table graphicRef71028 \" href=\"UTD.htm?16/37/16987\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      SPECIAL PRECAUTIONS WITH PULMONARY EMBOLISM",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Recurrent PE",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients being treated for a pulmonary embolism are at an increased risk for developing another PE, although this risk is significantly smaller when heparin or warfarin (Coumadin&reg;) is used. However, all patients should watch for signs of a new PE, including new chest pain with difficulty breathing, a rapid heart rate, or lightheadedness. This complication can be life-threatening and requires",
"     <strong>",
"      immediate attention",
"     </strong>",
"     . Emergency medical services are available in most areas of the United States by calling 911.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Anticoagulants such as heparin and Coumadin&reg; can have serious side effects and should be taken",
"     <strong>",
"      exactly",
"     </strong>",
"     as directed. If a dose is forgotten, the patient should call their provider or clinic for advice. The dose should not be changed to make up for missed doses. Patients should immediately report to the pharmacist or physician if the pill or tablet looks different than the previous bottle.",
"    </p>",
"    <p>",
"     Other precautions are necessary when taking Coumadin, which are outlined in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Patients may bleed easily while taking anticoagulants. Bleeding may develop in many areas, such as the nose or gums, excessive menstrual bleeding, bleeding in the urine or feces, bleeding or excessive bruising in the skin, as well as vomiting material that is bright red or like coffee grounds. In some cases, bleeding can develop inside the body and not be noticed immediately. Bleeding inside the body can cause a person to feel faint, or have pain in the back or abdomen. A healthcare provider should be notified immediately if there are any signs of this problem.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Wear an alert tag",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who take anticoagulants should wear a bracelet, necklace, or similar alert tag at all times. If medical treatment is required and the person is too ill to explain their condition, the tag will alert responders about the patient's use of anticoagulants and the risk of excessive bleeding.",
"    </p>",
"    <p>",
"     The alert tag should list the person's medical conditions, as well as the name and phone number of an emergency contact.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h3\">",
"      Reduce the risk of bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some simple modifications can limit the risk of bleeding:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Use a soft bristle toothbrush",
"      </li>",
"      <li>",
"       Floss with waxed floss rather than unwaxed floss",
"      </li>",
"      <li>",
"       Shave with an electric razor rather than a blade",
"      </li>",
"      <li>",
"       Take care when using scissors or knives",
"      </li>",
"      <li>",
"       Avoid potentially harmful activities (eg, contact sports)",
"      </li>",
"      <li>",
"       Do not take aspirin or other NSAIDS (eg, ibuprofen, Advil, Aleve, Motrin, Nuprin) while taking warfarin. Other nonprescription pain medications, such as acetaminophen, may be a safe alternative.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287530269\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292595416\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=see_link\">",
"      Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/45/4819?source=see_link\">",
"      Patient information: Pleuritic chest pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=see_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292595433\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"      Patient information: The nephrotic syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/16/16642?source=see_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H30\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/1/28697?source=see_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43961?source=see_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10503?source=see_link\">",
"      Chronic thromboembolic pulmonary hypertension: Surgical treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.americanheart.org/\">",
"      www.americanheart.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/29/2517/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/29/2517?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2517/abstract/1\">",
"      Kelman CW, Kortt MA, Becker NG, et al. Deep vein thrombosis and air travel: record linkage study. BMJ 2003; 327:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2517/abstract/2\">",
"      Chee YL, Watson HG. Air travel and thrombosis. Br J Haematol 2005; 130:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2517/abstract/3\">",
"      Rathbun SW, Whitsett TL, Vesely SK, Raskob GE. Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest 2004; 125:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2517/abstract/4\">",
"      Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2517/abstract/5\">",
"      Tapson VF, Carroll BA, Davidson BL, et al. The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med 1999; 160:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2517/abstract/6\">",
"      Roy PM, Colombet I, Durieux P, et al. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ 2005; 331:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2517/abstract/7\">",
"      Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002; 40:1660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_29_2517=[""].join("\n");
var outline_f2_29_2517=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PULMONARY EMBOLISM OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PULMONARY EMBOLISM RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           PULMONARY EMBOLISM SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           PULMONARY EMBOLISM DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           PULMONARY EMBOLISM TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           PULMONARY EMBOLISM PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           SPECIAL PRECAUTIONS WITH PULMONARY EMBOLISM",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H29\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?16/37/16987\" title=\"table 1\">",
"           Travel tips PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_29_2518="Diclofenac (topical): Patient drug information";
var content_f2_29_2518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diclofenac (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=see_link\">",
"     see \"Diclofenac (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=see_link\">",
"     see \"Diclofenac (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flector&reg;;",
"     </li>",
"     <li>",
"      Pennsaid&reg;;",
"     </li>",
"     <li>",
"      Solaraze&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg; Gel",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8016849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pennsaid&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg; Emulgel&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat precancerous skin wounds. It may take 1 month to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701936",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diclofenac or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use on skin that has any problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2810666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin gel, skin solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wash your hands after use if putting on the hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin gel:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use sunscreen or other drugs on affected part.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not bathe, shower, or swim after putting on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch falls off, put a new one on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the patch loosens, put tape over it to hold it in place.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2810659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on clean, dry, healthy skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2810661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 10 drops at a time. Repeat until a total of 40 drops has been put on knee. You may put right on the knee",
"       <b>",
"        or",
"       </b>",
"       on the hand and then onto the knee.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2810662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spread evenly on front, back, and side of knee.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Let dry before covering with clothing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2811158",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not bathe, shower, or swim for 30 minutes after applying.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2810663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may use cosmetics, lotions, insect repellant, sunscreen, or other skin drugs after the skin has dried.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2810665",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use heat or bandages on the treated part.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699338",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze gel.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect gel from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After you take off a skin patch, be sure to fold the sticky sides of the patch to each other.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away unused patches when they are no longer needed. Take them from the pouch, take off liner, and fold in half.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11658 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2518=[""].join("\n");
var outline_f2_29_2518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016848\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016849\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030940\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030942\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030941\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030946\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030947\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030949\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030944\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030945\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030950\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030951\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/63/15348?source=related_link\">",
"      Diclofenac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10036?source=related_link\">",
"      Diclofenac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/43/8890?source=related_link\">",
"      Diclofenac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/32/20998?source=related_link\">",
"      Diclofenac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=related_link\">",
"      Diclofenac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=related_link\">",
"      Diclofenac (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=related_link\">",
"      Diclofenac (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_29_2519="Intrapartum and postpartum management of insulin and blood glucose";
var content_f2_29_2519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrapartum and postpartum management of insulin and blood glucose",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/29/2519/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2519/contributors\">",
"     Siri L Kjos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/29/2519/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2519/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2519/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/29/2519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2519/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/29/2519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnancies complicated by diabetes mellitus, a key therapeutic goal during labor is to avoid maternal hyperglycemia, which increases the risk of fetal acidemia and neonatal hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/1\">",
"     1",
"    </a>",
"    ]. Glucose management postpartum is less critical, but remains a concern because of the potential for maternal hypoglycemia. Postdelivery glucose management is challenging because of the large and rapid changes in maternal hormone concentrations after delivery of the placenta.",
"   </p>",
"   <p>",
"    Maternal glucose concentration in the intrapartum period is affected by the mother's type of diabetes (type 1, type 2, or gestational) and the phase of labor that she is in (latent versus active). Women with type 1 diabetes mellitus have no endogenous insulin production, whereas those with type 2 and gestational diabetes generally have sufficient basal insulin secretion to avoid diabetic ketosis. The latent phase of labor is characterized by slow cervical change over hours, but the length varies greatly. When labor is induced, the latent phase may extend beyond 24 hours. The latent phase causes minimal change in maternal metabolic demands. In contrast, active labor is a period of relatively rapid cervical dilatation with fetal descent and, ultimately, delivery of the infant. It occurs over a few hours and should be viewed as intense exercise, with increased energy expenditure and decreased insulin requirements.",
"   </p>",
"   <p>",
"    In this topic review, we will assume that women with diabetes have entered labor with well-controlled glucose levels during the antecedent pregnancy. Women with poorly controlled pregestational diabetes entering labor may require larger doses of insulin. Their newborns are likely to have severe and prolonged hypoglycemia secondary to pancreatic hyperplasia and hyperinsulinemia, which are manifestations of diabetic fetopathy. Maternal normoglycemia during labor in these cases cannot prevent neonatal hypoglycemia once fetal pancreatic hyperplasia and excessive in utero insulin secretion have been established in response to a prolonged period of antenatal hyperglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO INTRAPARTUM GLYCEMIC CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most protocols for intrapartum management of diabetes rely on a combination of glucose and insulin infusion to maintain target glucose ranges. Clinical evidence does not support one intrapartum management protocol over another. This evidence is largely retrospective and derived primarily from women with type 1 diabetes, or from groups of women with both pre- and gestational diabetes treated with the same protocol, thus not accounting for the probable differences between women with different underlying metabolic disorders. In the absence of high quality evidence from well designed randomized trials, we will present the components of intrapartum glycemic management and provide sample protocols.",
"   </p>",
"   <p>",
"    Three protocols are presented (",
"    <a class=\"graphic graphic_table graphicRef76661 \" href=\"UTD.htm?13/25/13725\">",
"     table 1",
"    </a>",
"    ); protocols 1 and 2 are recommended by the American Diabetes Association Technical Reviews and Consensus Recommendations for Care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/2\">",
"     2",
"    </a>",
"    ]. Protocols 1 and 2 were designed for women with pregestational diabetes, but can be used in women with gestational diabetes. The third protocol (\"Rotating fluids protocol\") is from a randomized clinical trial demonstrating efficacy in women with primarily gestational diabetes (and a small number with type 2 diabetes), and should not be used in women with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intrapartum glucose targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists' and the American College of Endocrinology's goal for intrapartum glycemic control is glucose levels between 70 to 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.9 to 6.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This goal applies to women with type 1, type 2, or gestational diabetes. It was derived from neonatal outcome data obtained from observational studies, primarily involving women with type 1 diabetes.",
"   </p>",
"   <p>",
"    Some experts recommend a lower upper target (&lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    to minimize the risk of neonatal hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/2,6\">",
"     2,6",
"    </a>",
"    ], while others support more relaxed control (upper target 126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    citing data that the risk of clinically significant neonatal hypoglycemia is not significantly increased at this level [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and possibly not increased at predelivery glucose measurements as high as 144",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/9\">",
"     9",
"    </a>",
"    ]. Maternal glucose levels &gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    however, consistently appear to be associated with neonatal hypoglycemia and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intrapartum glucose and insulin requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with type 1 diabetes, studies using glucose-controlled insulin infusion systems have demonstrated that a basal insulin infusion is required to maintain euglycemia during the latent phase of spontaneous and induced labor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As active labor ensues, the requirement for insulin infusion drops to almost zero and the glucose infusion requirement increases to about 2.5",
"    <span class=\"nowrap\">",
"     mg/kg/min",
"    </span>",
"    to maintain maternal glucose concentration at 70 to 90",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    this is an eight-fold increase in glucose substrate. This glucose requirement is analogous to that observed with sustained and vigorous exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucose monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapid changes in glucose and insulin requirements during labor mandate frequent monitoring of capillary blood glucose concentration: a standard approach is every two to four hours during the latent phase, every one to two hours during the active phase, and every hour during insulin infusion.",
"   </p>",
"   <p>",
"    An exception is women with gestational diabetes who maintain euglycemia antenatally with diet and exercise therapy alone. These women rarely require insulin during labor so capillary blood glucose levels can be measured on admission and then approximately every four to six hours.",
"   </p>",
"   <p>",
"    Capillary blood glucose measurements are convenient and reasonably accurate over the normal range of blood glucose concentrations. However, overt hypoglycemia (&lt;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    or hyperglycemia (&gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    should be treated promptly. Capillary blood glucose levels are more variable and each type of glucose meter has a manufacture's limit of accuracy for a range of capillary blood glucose values. Thus, capillary blood glucose values outside of these ranges should be confirmed by venous blood measurements, which can be tested first at the bedside with a glucose meter and then in the laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Administration of intravenous glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glucose demands of active labor rapidly deplete hepatic stores of glycogen, necessitating caloric supplementation during the active phase. Since maternal oral intake is often limited during active labor because of the risk of aspiration pneumonitis, most women with diabetes are given glucose intravenously.",
"   </p>",
"   <p>",
"    During latent phase, maternal glucose demands can generally be met by stored hepatic glucose, unless the latent phase is protracted. Some protocols for women with type 1 diabetes begin with an isotonic saline infusion alone until the maternal glucose level falls to below the lower end of the target range (&lt;70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.9",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    and then begin the glucose infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/2,4,10\">",
"     2,4,10",
"    </a>",
"    ]. Other protocols begin with both glucose infusion (5% dextrose at 100 to 125",
"    <span class=\"nowrap\">",
"     mg/hour)",
"    </span>",
"    and insulin infusion (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     units/hour)",
"    </span>",
"    simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Both strategies appear to be effective and have low complication rates.",
"   </p>",
"   <p>",
"    One trial evaluated a rotating fluid approach by randomly assigning women with gestational and type 2 diabetes to receive either (1) a continuous insulin drip titrated to a target capillary blood glucose of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    plus 5% dextrose normal saline at 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    or (2) rotating fluids, which consisted of 5% dextrose normal saline at 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    when the blood glucose was &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    lactated Ringers at 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    when the capillary blood glucose was 101 to 140",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    and insulin infusion when the capillary blood glucose was &gt;140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/3\">",
"     3",
"    </a>",
"    ]. Both groups achieved similar intrapartum glucose levels (103",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and had no significant differences in neonatal hypoglycemia or neonatal intensive care unit admission. This small trial was limited to women with gestational (80 percent of subjects) and type 2 (20 percent of subjects) diabetes (ie, women who should have intact basal insulin secretion and thus should not be prone to ketosis). The safety of a rotating fluid strategy has not been demonstrated in women with type 1 diabetes, who can develop ketosis.",
"   </p>",
"   <p>",
"    Administration of glucose may also be important for optimal myometrial function. A randomized clinical trial in nulliparous women reported that intrapartum administration of either a 5% or 10% dextrose normal saline infusion significantly shortened labor compared with normal saline infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Administration of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin is administered intravenously and titrated to achieve glycemic targets. Most commonly, the insulin infusion",
"    <span class=\"nowrap\">",
"     (unit/hour)",
"    </span>",
"    is increased or decreased incrementally with increasing or decreasing maternal capillary blood glucose levels, which are measured hourly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/2,5-8,10-13\">",
"     2,5-8,10-13",
"    </a>",
"    ]. An alternative method is to add 10 units of regular or short-acting insulin to one liter of 5% dextrose normal saline. An infusion rate of 100 to 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    will, in the majority of women, provide both good glycemic control and adequate substrate for the energy demands of labor (",
"    <a class=\"graphic graphic_table graphicRef76661 \" href=\"UTD.htm?13/25/13725\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with gestational diabetes who maintain euglycemia during pregnancy on diet and exercise therapy alone rarely require insulin during labor. Even when insulin is required antepartum to normalize glucose levels, only a minority of these women will need any insulin during labor. This was illustrated in a study using relaxed capillary blood glucose targets in which only 2 percent of women with diet-controlled and 3.5 percent of women with insulin controlled gestational diabetes required insulin to maintain capillary blood glucose levels less than 144",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CESAREAN DELIVERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Insulin or oral anti-diabetic agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cesarean delivery is planned, especially in a woman with type I diabetes, the procedure should be scheduled for early morning. She should take her usual nighttime dose of intermediate-acting insulin, oral anti-diabetic medication, or continuous insulin infusion (insulin pump) until admission to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/12\">",
"     12",
"    </a>",
"    ]. If she uses a long-acting insulin at night, the dose needs to be decreased.",
"   </p>",
"   <p>",
"    The morning dose of insulin or oral anti-diabetic agent is held and the patient is given nothing by mouth. However, if surgery is delayed until the afternoon, basal insulin (about one-third of the morning intermediate insulin dose) is given with a 5% dextrose infusion to avoid ketosis. Glucose levels need to be monitored to adjust insulin therapy. A short-acting insulin can be given, as needed to control hyperglycemia, during this period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucose monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose should be monitored during the cesarean delivery if the operation is prolonged or complicated, in order to maintain euglycemia. Hyperglycemia during surgery should be avoided to minimize the risk of wound infection and metabolic complications in the mother, as well as neonatal hypoglycemia. Postoperative glucose levels are initially monitored every two hours until stable (70 to 150",
"    <span class=\"nowrap\">",
"     mg/dL);",
"    </span>",
"    a 5% dextrose infusion is administered to avoid ketosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"     \"Perioperative management of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glucose and fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal saline is used for intravenous hydration before operative anesthesia to avoid administering a large glucose bolus, which reduces umbilical cord pH and can cause neonatal hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INDUCTION OF LABOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Insulin or anti-diabetic medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with cesarean delivery, inductions should be scheduled to begin early in the morning and the patient should take her usual nighttime dose of intermediate-acting insulin, oral anti-diabetic medication, or continuous insulin infusion (insulin pump) until admission to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/12\">",
"     12",
"    </a>",
"    ]. If she uses a long-acting insulin at night, the dose needs to be decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Energy supplementation is needed during a prolonged labor induction, especially when additional time is needed for cervical ripening. Since many labor unit protocols prohibit oral intake during labor, 5 percent or 10 percent intravenous dextrose is given when maternal glucose levels drop below 60 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3 to 5.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/2,4,10\">",
"     2,4,10",
"    </a>",
"    ]. As discussed above, some protocols begin glucose infusion concurrently with insulin infusion, especially in women treated with insulin during pregnancy.",
"   </p>",
"   <p>",
"    Our institution permits oral intake during cervical",
"    <span class=\"nowrap\">",
"     ripening/latent",
"    </span>",
"    phase when",
"    <span class=\"nowrap\">",
"     ripening/latency",
"    </span>",
"    is anticipated to exceed 8 to 12 hours and there is a low risk of emergency operative delivery (eg, Category I fetal heart rate tracing, normal fetal growth and amniotic fluid index). During the",
"    <span class=\"nowrap\">",
"     ripening/latent",
"    </span>",
"    phase, women are allowed a reduced caloric diet (1200 to 1400 kcal) and pre-meal short-acting insulin is adjusted to the capillary blood glucose level and the carbohydrate intake. Intravenous fluids (5% dextrose or normal saline) are generally not needed if oral intake is sufficient.",
"   </p>",
"   <p>",
"    Capillary blood glucose levels are checked pre- and post-meal, maintaining the woman's normal prenatal",
"    <span class=\"nowrap\">",
"     day/night",
"    </span>",
"    rhythm until she enters into active labor, at which time management is as described above (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Glucose monitoring'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTPARTUM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immediate postpartum period",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery of the placenta, the insulin resistant state that characterizes pregnancy rapidly disappears. Women with pregestational diabetes need close glucose monitoring since insulin requirements drop precipitously.",
"   </p>",
"   <p>",
"    Post cesarean delivery, insulin may still be required even though women are consuming few calories. To avoid severe hypoglycemia from over administration of insulin, a short-acting insulin is administered on a sliding scale with the goal of maintaining relaxed glucose levels, about 140 to 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 to 8.9",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    during the first 24 to 48 hours. The following table is an example of a sliding scale using subcutaneous short-acting insulin (note the lesser amounts of insulin at bedtime to avoid nocturnal hypoglycemia) (",
"    <a class=\"graphic graphic_table graphicRef66187 \" href=\"UTD.htm?23/25/23964\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Women with type 1 diabetes who deliver vaginally and are able to eat require about one-third to one-half of their prepartum long-acting (eg, glargine) or intermediate-acting (NPH) insulin dose to meet postpartum basal needs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. Similarly, their regular or short-acting premeal doses need to be decreased by about one-third to one-half.",
"   </p>",
"   <p>",
"    Women with type 2 diabetes may not require any medication during the first 24 to 48 hours postpartum. If they require insulin and are eating, they can be started on 0.6",
"    <span class=\"nowrap\">",
"     units/Kg",
"    </span>",
"    postpartum weight. Alternatively, oral agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    , can be started after 24 to 48 hours and prior to discharge. These agents can be safely used while breastfeeding. Generally, women with type 2 diabetes need only monitor fasting capillary blood glucose levels during the first few weeks postpartum. Metformin is the preferred agent for obese type 2 diabetic patients and does not produce hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with gestational diabetes who have fasting venous glucose levels below 126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    after delivery can be counseled to continue to follow their diet, exercise, and achieve a healthy weight to prevent diabetes. They should undergo a two-hour, 75 g oral glucose tolerance test six to eight weeks after delivery to establish glucose status. Self-monitoring of capillary blood glucose levels is not indicated at hospital discharge. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with gestational and pregestational diabetes are strongly encouraged to breastfeed for its health benefits to mother and newborn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link\">",
"     \"Maternal and economic benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breastfeeding requires an additional 500 kcal per day, taken as 100 g of carbohydrate and 20 g of protein. Blood glucose levels can drop rapidly during nursing due to the high metabolic demand. Thus, self-monitoring of glucose is important during the early postpartum period, especially in women with type 1 diabetes.",
"   </p>",
"   <p>",
"    The use of insulin and anti-hyperglycemic agents in breastfeeding mothers is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H28#H28\">",
"     \"Principles of medication use during lactation\", section on 'Anti-hyperglycemic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     After hospital discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;After discharge, standard diabetes management can be resumed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2519/abstract/16\">",
"     16",
"    </a>",
"    ]. Glycemic targets at this time are: glycated hemoglobin &lt;7.0 percent, premeal glucose concentration &lt;120",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and two-hour postprandial glucose concentration &lt;170",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with diabetes, the key therapeutic goal during labor is to avoid maternal hyperglycemia, which increases the risk of fetal acidemia and neonatal hypoglycemia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American College of Obstetricians and Gynecologists' and the American College of Endocrinology's goal for intrapartum glycemic control is glucose levels between 70 to 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.9 to 6.1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to intrapartum glycemic control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women requiring insulin prepregnancy, a basal insulin infusion is likely to be required to maintain euglycemia during the latent phase of induced labor. As active labor ensues, the insulin requirement drops to almost zero and glucose requirements increase to about 2.5",
"      <span class=\"nowrap\">",
"       mg/kg/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intrapartum glucose and insulin requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reasonable approaches for women with type 1 diabetes are either to begin with an isotonic saline infusion alone until the maternal glucose level falls to below the target range (&lt;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.9",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      and then begin the glucose infusion or to begin with both glucose infusion (5% dextrose at 100 to 125",
"      <span class=\"nowrap\">",
"       mg/hour)",
"      </span>",
"      and insulin infusion (0.5 to 1.0",
"      <span class=\"nowrap\">",
"       units/hour)",
"      </span>",
"      simultaneously. Both strategies appear to be effective and have low complication rates. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Administration of intravenous glucose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women requiring insulin prepregnancy, capillary blood glucose should be monitored every two to four hours during the latent phase, every one to two hours during the active phase, and every hour during insulin infusion. Women with gestational diabetes well controlled antenatally with diet and exercise therapy alone do not require frequent glucose monitoring intrapartum. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Glucose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The insulin infusion is increased or decreased incrementally with increasing or decreasing maternal capillary blood glucose levels, which are measured hourly. An alternative method is to add 10 units of regular or short-acting insulin to one liter of 5% dextrose normal saline. An infusion rate of 100 to 125",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      will, in the majority of women, provide both good glycemic control and adequate substrate for the energy demands of labor. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Administration of insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After delivery of the placenta, the insulin resistant state that characterizes pregnancy rapidly disappears. Women with pregestational diabetes need close glucose monitoring since insulin requirements drop precipitously. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Postpartum management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/1\">",
"      Mimouni F, Miodovnik M, Siddiqi TA, et al. Perinatal asphyxia in infants of insulin-dependent diabetic mothers. J Pediatr 1988; 113:345.",
"     </a>",
"    </li>",
"    <li>",
"     Conway DL, Catalano PM. Management of delivery. In: Managing Preexisting Diabetes and Pregnancy. Technical Reviews and Consensus Recommendations for Care, Kitzmiller JL, Jovaniovic L, Brown F, Coustan D, Reader DM (Eds) (Eds), American Diabetes Association, Alexandria, VA 2008. p.584.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/3\">",
"      Rosenberg VA, Eglinton GS, Rauch ER, Skupski DW. Intrapartum maternal glycemic control in women with insulin requiring diabetes: a randomized clinical trial of rotating fluids versus insulin drip. Am J Obstet Gynecol 2006; 195:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/4\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005; 105:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/5\">",
"      Garber AJ, Moghissi ES, Bransome ED Jr, et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004; 10 Suppl 2:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/6\">",
"      Curet LB, Izquierdo LA, Gilson GJ, et al. Relative effects of antepartum and intrapartum maternal blood glucose levels on incidence of neonatal hypoglycemia. J Perinatol 1997; 17:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/7\">",
"      Kline GA, Edwards A. Antepartum and intra-partum insulin management of type 1 and type 2 diabetic women: Impact on clinically significant neonatal hypoglycemia. Diabetes Res Clin Pract 2007; 77:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/8\">",
"      Carron Brown S, Kyne-Grzebalski D, Mwangi B, Taylor R. Effect of management policy upon 120 Type 1 diabetic pregnancies: policy decisions in practice. Diabet Med 1999; 16:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/9\">",
"      Barrett HL, Morris J, McElduff A. Watchful waiting: a management protocol for maternal glycaemia in the peripartum period. Aust N Z J Obstet Gynaecol 2009; 49:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/10\">",
"      Jovanovic L, Peterson CM. Insulin and glucose requirements during the first stage of labor in insulin-dependent diabetic women. Am J Med 1983; 75:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/11\">",
"      Jovanovic L. Glucose and insulin requirements during labor and delivery: the case for normoglycemia in pregnancies complicated by diabetes. Endocr Pract 2004; 10 Suppl 2:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/12\">",
"      Gabbe SG, Carpenter LB, Garrison EA. New strategies for glucose control in patients with type 1 and type 2 diabetes mellitus in pregnancy. Clin Obstet Gynecol 2007; 50:1014.",
"     </a>",
"    </li>",
"    <li>",
"     Kitzmiller, JL, Gavin, L. Preexisting diabetes and pregnancy. In: Manual of Endocrinology and Metabolism, 3rd ed, Lavin, N (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2002. p.660-665.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/14\">",
"      Lepercq J, Abbou H, Agostini C, et al. A standardized protocol to achieve normoglycaemia during labour and delivery in women with type 1 diabetes. Diabetes Metab 2008; 34:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/15\">",
"      Shrivastava VK, Garite TJ, Jenkins SM, et al. A randomized, double-blinded, controlled trial comparing parenteral normal saline with and without dextrose on the course of labor in nulliparas. Am J Obstet Gynecol 2009; 200:379.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2519/abstract/16\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4441 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2519=[""].join("\n");
var outline_f2_29_2519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO INTRAPARTUM GLYCEMIC CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intrapartum glucose targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intrapartum glucose and insulin requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucose monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Administration of intravenous glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Administration of insulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CESAREAN DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Insulin or oral anti-diabetic agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucose monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glucose and fluids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INDUCTION OF LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Insulin or anti-diabetic medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immediate postpartum period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      After hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/25/13725\" title=\"table 1\">",
"      Intrapartum rx diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/25/23964\" title=\"table 2\">",
"      Sliding insulin scale for postpartum mgt of glucose levels",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_29_2520="Bisoprolol: Drug information";
var content_f2_29_2520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bisoprolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/59/22453?source=see_link\">",
"    see \"Bisoprolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zebeta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Bisoprolol&reg;;",
"     </li>",
"     <li>",
"      Ava-Bisoprolol;",
"     </li>",
"     <li>",
"      Mylan-Bisoprolol;",
"     </li>",
"     <li>",
"      Novo-Bisoprolol;",
"     </li>",
"     <li>",
"      PHL-Bisoprolol;",
"     </li>",
"     <li>",
"      PMS-Bisoprolol;",
"     </li>",
"     <li>",
"      PRO-Bisoprolol;",
"     </li>",
"     <li>",
"      Sandoz-Bisoprolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Beta-1 Selective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 2.5-5 mg once daily; may be increased to 10 mg and then up to 20 mg once daily, if necessary; usual dose range (JNC 7): 2.5-10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure (unlabeled use):",
"     </b>",
"     Oral: Initial: 1.25 mg once daily; maximum recommended dose: 10 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Increase dose gradually and monitor for signs and symptoms of CHF (Hunt, 2009; Lindenfeld, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F141643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: Initial: 2.5 mg daily; increase cautiously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15800538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatitis or cirrhosis: Initial: 2.5 mg daily; increase cautiously.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as fumarate: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zebeta&reg;: 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zebeta&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other agents",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F141677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic stable angina, supraventricular arrhythmias, PVCs, heart failure (HF)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F141689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zebeta&reg; may be confused with DiaBeta&reg;, Zetia&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (dose related; 6% to 8%), insomnia (2% to 3%), hypoesthesia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (dose related; 3% to 4%), nausea (2%), vomiting (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (2% to 3%), weakness (dose related; &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (5%), rhinitis (3% to 4%), sinusitis (dose related; 2%), dyspnea (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, acne, alopecia, angioedema, anxiety, arrhythmia, asthma, back/neck pain, bradycardia (dose related), bronchitis, bronchospasm, BUN/creatinine increased, claudication, cold extremities, confusion (especially in the elderly), congestive heart failure, constipation, coughing, cutaneous vasculitis, cystitis, depression, dermatitis, dizziness, dyspepsia, dyspnea on exertion, eczema, edema, exfoliative dermatitis, flushing, gastritis, gout, hallucinations, headache, hearing decreased, hyperesthesia, hyperglycemia, hyperkalemia, hyperphosphatemia, hypertriglyceridemia, hypotension, impotence, lacrimation (abnormal), leukopenia, libido decreased, malaise, memory loss, muscle cramps, muscle/joint pain, nervousness, ocular pain/pressure, orthostatic hypotension, palpitations, paresthesia, peptic ulcer, Peyronie's disease, pharyngitis, polyuria, positive ANA titers, pruritus, psoriasis, psoriasiform eruption, purpura, rash, renal colic, restlessness, rhythm disturbances, sleep disturbances, somnolence, syncope, taste abnormality, thrombocytopenia, tinnitus, transaminases increased, tremor, twitching, uric acid increased, vasculitis, vertigo, visual disturbances, weight gain, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cardiogenic shock; overt cardiac failure; marked sinus bradycardia or heart block greater than first-degree (except in patients with a functioning artificial pacemaker)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse events:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; for patients with bronchospastic disease who do not respond to or cannot tolerate other therapies, initial low doses of beta",
"     <sub>",
"      1",
"     </sub>",
"     -selective bisoprolol may be employed and used cautiously with close monitoring. Ensure patient has an inhaled beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist immediately available. At doses &ge;20 mg/day, slight asymptomatic increases in airway resistance and decreases in forced expiratory volume (FEV",
"     <sub>",
"      1",
"     </sub>",
"     ) has been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated heart failure and monitor for a worsening of the condition. Patients should be stabilized on heart failure regimen prior to initiation of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and very careful titration. Adjustment of other medications (ACE inhibitors and/or diuretics) may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment required with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F141674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F141632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid garlic (may have increased antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F141622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies; therefore, the manufacturer classifies bisoprolol as pregnancy category C. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. Limited information is available related to the use of bisoprolol for the treatment of hypertension in pregnancy; other agents may be more appropriate for use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10570481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bisoprolol is excreted into breast milk. The manufacturer recommends that caution be exercised when administering bisoprolol to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F141623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F141621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bisoprolol Fumarate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $36.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $36.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zebeta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (30): $144.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $144.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F141611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, ECG; serum glucose regularly (in patients with diabetes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F141624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      B-Beta (ID);",
"     </li>",
"     <li>",
"      Beta-One (ID, KP);",
"     </li>",
"     <li>",
"      Betacor (TW);",
"     </li>",
"     <li>",
"      Bicor (AU);",
"     </li>",
"     <li>",
"      Biol (CH);",
"     </li>",
"     <li>",
"      Bipro (ID);",
"     </li>",
"     <li>",
"      Biscor (ID, TW);",
"     </li>",
"     <li>",
"      Biso 5 (TW);",
"     </li>",
"     <li>",
"      Bisohexal (SG);",
"     </li>",
"     <li>",
"      Bisol (MY);",
"     </li>",
"     <li>",
"      Bisolol (IL);",
"     </li>",
"     <li>",
"      Bisomerck (DE);",
"     </li>",
"     <li>",
"      Bispro (AU);",
"     </li>",
"     <li>",
"      Biteven (TW);",
"     </li>",
"     <li>",
"      Cardensiel (FR);",
"     </li>",
"     <li>",
"      Cardicor (DK, IE);",
"     </li>",
"     <li>",
"      Cardiloc (IL);",
"     </li>",
"     <li>",
"      Concor (AR, AT, BB, BG, BR, BS, CH, CL, CN, CO, CR, CZ, DE, EC, EE, EG, GT, HK, HN, HR, HU, ID, IN, IT, JM, KP, LU, MX, MY, NI, NL, PA, PE, PK, PL, PT, RU, SV, TH, TR, TT, TW, VE, ZA);",
"     </li>",
"     <li>",
"      Concor COR (DE);",
"     </li>",
"     <li>",
"      Concore (PH);",
"     </li>",
"     <li>",
"      Corbis (AR);",
"     </li>",
"     <li>",
"      Corentel (PE, PY, UY);",
"     </li>",
"     <li>",
"      Detensiel (FR);",
"     </li>",
"     <li>",
"      Emconcor (BE, DK, ES, FI, NO, SE);",
"     </li>",
"     <li>",
"      Emcor (GB);",
"     </li>",
"     <li>",
"      Euradal (ES);",
"     </li>",
"     <li>",
"      Hapsen (ID);",
"     </li>",
"     <li>",
"      Hypercor (TH);",
"     </li>",
"     <li>",
"      Isoten (BE);",
"     </li>",
"     <li>",
"      Jutabis (DE);",
"     </li>",
"     <li>",
"      Kenco (TW);",
"     </li>",
"     <li>",
"      Maintate (JP);",
"     </li>",
"     <li>",
"      Monocor (TW);",
"     </li>",
"     <li>",
"      Novacor (TH);",
"     </li>",
"     <li>",
"      Pactens (GR);",
"     </li>",
"     <li>",
"      Soprol (DO, IE);",
"     </li>",
"     <li>",
"      Vasoten (MY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective inhibitor of beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors; competitively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors, with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors at doses &le;20 mg",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and almost complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely; highest concentrations in heart, liver, lungs, and saliva; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic; significant first-pass effect (~20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 9-12 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute: 27-36 hours; Hepatic cirrhosis: 8-22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% as unchanged drug, remainder as inactive metabolites); feces (&lt;2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2004, 44(3):671-719.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/15358045/pubmed\" id=\"15358045\" target=\"_blank\">",
"        15358045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenauer PK, Pekow P, Wang K, et al, &ldquo;Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(4):349-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/16049209/pubmed\" id=\"16049209\" target=\"_blank\">",
"        16049209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poldermans D, Boersma E, Bax JJ, et al, &ldquo;The Effect of Bisoprolol on Perioperative Mortality and Myocardial Infarction in High-Risk Patients Undergoing Vascular Surgery,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(24):1789-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/10588963/pubmed\" id=\"10588963\" target=\"_blank\">",
"        10588963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, \"Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 353(9146):9-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/10023943/pubmed\" id=\"10023943\" target=\"_blank\">",
"        10023943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Hear J",
"      </i>",
"      , 2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/29/2520/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9158 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-220.255.2.106-1001A7F1F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2520=[""].join("\n");
var outline_f2_29_2520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141637\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141638\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141681\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141641\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141642\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141643\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15800538\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141613\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141598\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460164\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141616\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141677\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141689\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141679\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141619\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141602\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141674\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141607\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141632\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141609\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141622\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141646\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10570481\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141623\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141621\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141611\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141624\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141601\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141618\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9158\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9158|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/59/22453?source=related_link\">",
"      Bisoprolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_29_2521="Nitrates in the management of stable angina pectoris";
var content_f2_29_2521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nitrates in the management of stable angina pectoris",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/29/2521/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2521/contributors\">",
"     Joseph P Kannam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2521/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/29/2521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2521/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/29/2521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/29/2521/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/29/2521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    was the first medication used in 1879 by William Murrell for the treatment of angina pectoris [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/1\">",
"     1",
"    </a>",
"    ] and, in its immediate release forms, still remains first-line drug therapy for many patients&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While they act as venodilators, coronary vasodilators, and modest arteriolar dilators, the primary antiischemic effect of nitrates is to decrease myocardial oxygen demand by producing systemic vasodilation more than coronary vasodilation. This systemic vasodilation reduces LV systolic wall stress.",
"   </p>",
"   <p>",
"    In patients with exertional stable angina, nitrates improve exercise tolerance, time to onset of angina, and ST-segment depression during exercise testing. In combination with beta blockers or calcium channel blockers, nitrates produce greater antianginal and antiischemic effects.",
"   </p>",
"   <p>",
"    Its use, however, is complicated by the development of tolerance with continuous therapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Nitrate tolerance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates dilate veins, arteries, and coronary arteries by relaxing vascular smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/4\">",
"     4",
"    </a>",
"    ]. They produce these effects by entering vascular smooth muscle cells where they are metabolized to 1,2-glyceryl dinitrate and nitrite, via mitochondrial aldehyde dehydrogenase-2 (ALDH2 or mtALDH), and then nitric oxide and S-nitrosothiols (",
"    <a class=\"graphic graphic_figure graphicRef50622 \" href=\"UTD.htm?10/21/10590\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/5\">",
"     5",
"    </a>",
"    ]. Sulfhydryl groups on ALDH2 are required for activity, which can explain the known sulfhydryl requirement for vascular smooth muscle relaxation by nitrates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the antiischemic efficacy of nitrates pertains to their ability to decrease myocardial oxygen demand as a result of systemic vasodilatation rather than any activity as a coronary vasodilator. Nitrates do not have a direct effect on cardiac chronotropy or inotropy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effect on systemic hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nitrates are primarily venodilators due to increased bioavailability to venous smooth muscle cells. Venodilation lowers preload (left ventricular end-diastolic pressure) and therefore reduces wall stress, resulting in a decrease in myocardial oxygen demand. The fall in preload is more pronounced with sitting or standing.",
"   </p>",
"   <p>",
"    At low doses, nitrates cause a lesser degree of arterial and arteriolar dilatation, leading to little or no change in systemic vascular resistance or blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/4\">",
"     4",
"    </a>",
"    ]. As the dose is increased, the blood pressure falls, often accompanied by reflex tachycardia. Wall stress is reduced at the lower blood pressure, resulting in a further decrease in myocardial oxygen demand.",
"   </p>",
"   <p>",
"    Some patients, especially those with hypovolemia, are extremely sensitive to the arteriolar effect of nitrates and develop a profound drop in blood pressure which can aggravate myocardial ischemia. In addition, arteriolar dilatation of the face can cause flushing and meningeal arterial dilatation can cause headache, two common side effects of these drugs.",
"   </p>",
"   <p>",
"    Problems can also occur with excessive venodilation. This can result in a marked decrease in venous return, which induces cardiac emptying that triggers mechanical receptors in the heart, possibly leading to hypotension and bradycardia consistent with the Bezold-Jarisch reflex (vasovagal response) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect on coronary hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nitrate-induced increase in coronary blood flow has been proposed as a potential mechanism for relieving ischemia. Animal and human studies have shown that nitrates dilate both normal and abnormal coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/7\">",
"     7",
"    </a>",
"    ]; this response is preserved in saphenous vein grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/8\">",
"     8",
"    </a>",
"    ]. The clinical importance of this effect is uncertain because the coronary arterioles in patients with a flow-limiting coronary stenosis are already dilated to maintain resting blood flow, making further coronary dilation during ischemia difficult.",
"   </p>",
"   <p>",
"    There are, however, settings in which a direct effect on coronary hemodynamics may be beneficial. Nitrates can reduce or reverse coronary vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, patients with primarily vasospastic angina or a large vasoconstrictor component to their angina can benefit from the direct coronary action of nitrate therapy. Nitrates also indirectly improve subendocardial blood flow as the reduction in left ventricular end-diastolic pressure induced by systemic venous dilatation decreases the resistance to coronary blood flow from epicardium to endocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, nitrates may lower the resistance to collateral vessel blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antiplatelet and antithrombotic properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates have significant antiplatelet and antithrombotic properties; however the clinical importance of these potentially beneficial effects is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/12\">",
"     12",
"    </a>",
"    ]. Stimulation of platelet guanylate cyclase by nitrates prevents fibrinogen binding to platelet",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptors, which is essential for platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/13\">",
"     13",
"    </a>",
"    ]. Transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    has been shown to inhibit platelet aggregation and thrombus formation in patients with angina [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NITRATE TOLERANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tolerance has been a major problem with the use of nitrates as chronic antianginal therapy. It was first observed in individuals exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    during the production of explosives. These workers developed severe headache and dizziness after the initial exposure. These side effects would then diminish after several days. If, however, exposure was avoided for several days, the symptoms would return after reexposure.",
"   </p>",
"   <p>",
"    A similar sequence occurs in humans as chronic nitrate therapy for angina pectoris is associated with attenuation and at times abolition of the hemodynamic and antianginal effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanisms of tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;How nitrate tolerance occurs is incompletely understood. It is due to attenuation of the vascular effect of nitrates, not to altered pharmacokinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least three, not mutually exclusive, mechanisms have been proposed to explain the development of nitrate tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/2\">",
"     2",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      bioconversion to 1,2-glyceryl dinitrate with decreased formation of nitric oxide. This effect is nitrate-specific and is not seen with non-nitrate sources of nitric oxide such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/15\">",
"       15",
"      </a>",
"      ]. Consistent with this theory are the experimental observations that there is no tolerance to the effect of S-nitrosothiols and that the activity of mtALDH, the enzyme required for metabolism of nitrates to 1,2-glyceryl dinitrate in markedly reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/5\">",
"       5",
"      </a>",
"      ]. The same findings can be induced by inhibitors of mtALDH [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced bioactivity of nitric oxide&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/16\">",
"       16",
"      </a>",
"      ]. Consistent with this theory is the finding in an animal study that vascular and hemodynamic tolerance to nitrates occurred despite high levels of nitric oxide and rates of nitric oxide formation that were similar in those animals that were not tolerant [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/17\">",
"       17",
"      </a>",
"      ]. Also in support of this hypothesis is that transgenic animals that overexpress endothelial nitric oxide synthase have chronically elevated nitric oxide release, which is associated with reduced vascular reactivity to nitric oxide-mediated vasodilators [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Activation of the vasoconstrictor renin-angiotensin-aldosterone and sympathetic nervous systems in response to nitrate-induced vasodilation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. There is also increased peripheral sensitivity to these vasoconstrictors, an effect that can be reversed by angiotensin converting enzyme inhibition [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/19\">",
"       19",
"      </a>",
"      ]. Abnormal coronary vasoconstrictor responses have also been described with continuous nitrate exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several strategies have been attempted to prevent nitrate tolerance, the most effective being intermittent therapy with an adequate nitrate-free interval. It is thought that a nitrate-free interval permits the regeneration of reduced sulfhydryl groups, thereby restoring vascular responsiveness to nitrates. Chronic therapy with N-acetylcysteine, a sulfhydryl donor, does not appear to be effective in patients with stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/22\">",
"     22",
"    </a>",
"    ], in contrast to its acute benefit with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    in those with unstable angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=see_link\">",
"     \"Nitrates in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, two concerns regarding intermittent therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A time-zero effect, which refers to a deterioration in exercise performance relative to placebo prior to the morning dose of nitrates.",
"     </li>",
"     <li>",
"      Rebound angina, which refers to an increase in angina during the nitrate-free interval. There may result from a supersensitivity of the vessel wall to vasoconstrictors [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/23\">",
"       23",
"      </a>",
"      ] or an increased vasomotor response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/35/6707?source=see_link\">",
"       acetylcholine",
"      </a>",
"      , suggesting the development of endothelial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these effects occur to a clinically significant degree remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Their importance with the different nitrate preparations will be discussed below.",
"   </p>",
"   <p>",
"    Several other methods have been proposed to reduce nitrate tolerance, although",
"    <strong>",
"     none",
"    </strong>",
"    is as yet used clinically:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      can reverse endothelial dysfunction, possibly by restoring the bioavailability of tetrahydrobiopterin, a cofactor for nitric oxide synthase",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arginine, its substrate. This suggests a possible role for folic acid in preventing nitrate tolerance. This was examined in a study of 18 subjects who were randomly assigned to folic acid (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo for one week; all patients received continuous transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      (0.6",
"      <span class=\"nowrap\">",
"       mg/hour)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/29\">",
"       29",
"      </a>",
"      ]. Compared to placebo, folic acid prevented the development of both endothelial dysfunction and nitrate tolerance.",
"     </li>",
"     <li>",
"      Treatment for five to 10 days with L-arginine, the substrate for nitric oxide synthesis, can modify or prevent the development of nitrate tolerance during continuous transdermal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      use [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       Hydralazine",
"      </a>",
"      may attenuate nitrate tolerance, perhaps by preventing superoxide generation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/31\">",
"       31",
"      </a>",
"      ]. This relationship could contribute to the efficacy of combined nitrate-hydralazine therapy in patients with heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .) In patients with angina pectoris, hydralazine should be given in combination with a beta blocker because of the reflex sympathetic activation.",
"     </li>",
"     <li>",
"      Other antioxidants may be helpful, at least from a theoretical perspective, such as vitamin E&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/32\">",
"       32",
"      </a>",
"      ] and vitamin C&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. In addition,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , a beta and alpha blocker that also has antioxidant activity, may prevent nitrate tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/35\">",
"       35",
"      </a>",
"      ]. The importance of antioxidant activity was suggested by a second report which compared carvedilol with another beta and alpha blocker (arotinolol) that was devoid of antioxidant properties; only carvedilol prevented nitrate tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other drugs have had variable or no effect. These include angiotensin converting enzyme (ACE) inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/19,37-39\">",
"     19,37-39",
"    </a>",
"    ], and diuretics, which may have some antianginal activity by reducing the plasma volume [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMMONLY USED NITRATE PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous nitrate preparations are commercially available, including sublingual, buccal, oral, spray, ointment, and transdermal preparations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sublingual nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    remains the therapy of choice for acute anginal episodes and prophylactically for activities known to elicit angina such as mowing the lawn, playing tennis, or walking in cold weather. Our impression is that the prophylactic use of nitroglycerin is not sufficiently emphasized to patients.",
"   </p>",
"   <p>",
"    The onset of action is within two to five minutes and the duration of action is 15 to 30 minutes. Tolerance is not a problem with sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    because of its intermittent administration, even in patients on chronic nitrate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    dose is 0.3 mg",
"    <span class=\"nowrap\">",
"     (1/200",
"    </span>",
"    grains) to 0.4 mg",
"    <span class=\"nowrap\">",
"     (1/150",
"    </span>",
"    grains). One-half the dose (0.15 mg or",
"    <span class=\"nowrap\">",
"     1/400",
"    </span>",
"    grains) can be used if the patient becomes hypotensive or develops symptoms such as headache or flushing with the higher doses. Elderly patients should be warned about potential lightheadedness, especially in warm weather.",
"   </p>",
"   <p>",
"    The traditional recommendation is for patients to take one",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    dose sublingually every five minutes for up to three doses before calling for emergency medical services (EMS) evaluation. However, studies suggest that this approach may result in significant delays in obtaining EMS assistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. As a result, the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend contacting EMS if chest pain or discomfort is unimproved or worsening five minutes after",
"    <strong>",
"     one",
"    </strong>",
"    nitroglycerin dose has been taken [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/44\">",
"     44",
"    </a>",
"    ]. No change to this approach was made in the 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients known to their providers to have frequent angina, physicians may consider a selected, more tailored message that takes into account the frequency and character of the patient's angina and their typical time course of response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    If the sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is potent, a slight tingling sensation should be felt under the tongue. Tablets that crumble easily should not be used. The sublingual mucosa should be moist for adequate dissolution and absorption of the tablet. A drink of water in patients with dry sublingual mucosa prior to ingestion of the tablet may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    tablets are both heat and light sensitive. They should therefore be stored in a tightly capped dark bottle in the refrigerator with only a small supply being carried by the patient. Nitroglycerin tablets in an opened bottle should be discarded after 12 months.",
"   </p>",
"   <p>",
"    Patient education is extremely important for the proper use of sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    . A survey of 50 patients revealed a surprising lack of knowledge concerning the administration, storage, and side effects of this preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/47\">",
"     47",
"    </a>",
"    ]. Only 12 percent knew the maximum dose in a 15 minute period, 28 percent knew the proper storage conditions for sublingual tablets, and 52 percent knew the most common side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nitroglycerin spray",
"    </span>",
"    &nbsp;&mdash;&nbsp;A less popular but equally effective means of administering sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is by metered dose spray. The spray dispenses of 0.4 mg of nitroglycerin. One to two sprays can be used at the start of an attack and up to three sprays can be used in a 15 minute period. It has a shelf life of two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Isosorbide dinitrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     Isosorbide dinitrate",
"    </a>",
"    (ISDN) has an onset of action within 15 to 30 minutes and the duration of action is three to six hours. Low bioavailability from hepatic metabolism has necessitated relatively large doses of 10 to 40 mg three times daily.",
"   </p>",
"   <p>",
"    The beneficial effects of a single dose of ISDN (15, 30, 60, 120 mg) were demonstrated in 12 patients with chronic stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/41\">",
"     41",
"    </a>",
"    ]. There was a dose-related reduction in systolic blood pressure that persisted for eight hours. Exercise duration improved up to eight hours after the 15 and 30 mg dose; there was no added benefit with the 60 and 120 mg doses (",
"    <a class=\"graphic graphic_figure graphicRef61032 \" href=\"UTD.htm?36/16/37134\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Unfortunately, tolerance has limited the usefulness of ISDN as a chronic antianginal agent. In the study above, ISDN was given four times daily for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/49\">",
"     49",
"    </a>",
"    ]: both the blood pressure and exercise responses were attenuated (",
"    <a class=\"graphic graphic_figure graphicRef61032 \" href=\"UTD.htm?36/16/37134\">",
"     figure 2",
"    </a>",
"    ). In particular, exercise duration was only increased for two hours after a dose and doses above 15 mg four times daily produced no added benefit. The development of tolerance occurred despite higher plasma concentrations of ISDN during maintenance therapy.",
"   </p>",
"   <p>",
"    Several studies have altered the drug regimen in an attempt to prevent the development of tolerance. One study, for example, examined the effect of 30 mg of ISDN given two (7 AM and 12 PM), three (7 AM, 12 PM, and 5 PM), and four (7 AM, 12 PM, 5 PM, and 11 PM) times daily for one week [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/50\">",
"     50",
"    </a>",
"    ]. Exercise duration until the onset of angina was assessed before and one, three, and five hours after the morning dose. After a single initial dose, exercise duration significantly increased versus placebo over the five hour observation period. After one week of therapy, two and three (but not four) times daily dosing was associated with improved exercise tolerance compared placebo; however, the benefit was less pronounced late in the day, indicating partial tolerance. One limitation to the clinical utility of these results is that the response was measured only to the morning dose of ISDN.",
"   </p>",
"   <p>",
"    Another report questioned the antianginal efficacy of three times daily ISDN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/51\">",
"     51",
"    </a>",
"    ]. Eight patients with chronic stable angina were given ISDN at 8 AM, 1 PM, and 6 PM. Exercise time increased for at most three hours after the morning and afternoon dose but not substantially after the evening dose (",
"    <a class=\"graphic graphic_figure graphicRef79122 \" href=\"UTD.htm?25/44/26317\">",
"     figure 3",
"    </a>",
"    ). It was concluded that ISDN given three times daily offered antianginal protection for at most six hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H520925516\">",
"    <span class=\"h2\">",
"     Isosorbide mononitrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosage and side-effects of the mononitrates are similar to those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Nitrate tolerance is a potential problem. This may be less of an issue with the use of the rapid-release preparations given approximately seven hours between doses (eg, 0800 and 1500 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/52\">",
"     52",
"    </a>",
"    ] or with the extended release preparation when given once daily in doses of either 120 and 240 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transdermal nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    patches obtained FDA approval in 1981 and gained wide acceptance for its convenience. These patches have either a polymer matrix or a silicone gel impregnated with nitroglycerin; a semipermeable membrane between the drug reservoir and the skin results in a constant delivery of nitroglycerin. Onset of action is 30 minutes with an 8 to 14 hour duration of action. The usual dose is 0.2 to 0.8",
"    <span class=\"nowrap\">",
"     mg/hr.",
"    </span>",
"   </p>",
"   <p>",
"    Once",
"    again, continuous therapy is associated with nitrate tolerance. In one report, for example, patches of 5, 10, 15, 30, and 45 mg were given continuously and treadmill walking time was examined after two, four, and 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/54\">",
"     54",
"    </a>",
"    ]. With the exception of the 45 mg dose, antianginal effects were seen at two and four hours but absent at 24 hours on the first day. Daily therapy with 15 mg patches for one to two weeks was associated with antianginal and hemodynamic effects that were not different from placebo patches. Similar findings were noted in a multicenter, randomized, placebo controlled trial involving 562 patients examined the efficacy of eight weeks of continuous transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/55\">",
"     55",
"    </a>",
"    ]. In doses ranging from 15 to 105",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    there was no difference in exercise tolerance or anginal frequency between active drug and placebo; this effect was noted within 24 hours.",
"   </p>",
"   <p>",
"    As a result of these findings, intermittent transdermal regimens have been evaluated. A recent trial evaluated the efficacy of three dose levels of transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (0.2, 0.4, and 0.8",
"    <span class=\"nowrap\">",
"     mg/hr)",
"    </span>",
"    applied for 12 hours daily for 30 days in 291 patients with chronic stable angina. After 30 days of therapy, treadmill walking time until the onset of angina or 1 mm ST depression was significantly improved in all treatment groups when compared to placebo. In addition, there was no evidence of rebound angina or partial tolerance when the antianginal effects on day 30 were compared to those on day 1 (",
"    <a class=\"graphic graphic_figure graphicRef51227 \" href=\"UTD.htm?6/59/7102\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This trial did not directly compare patch-on and patch-off periods and hence the problem of rebound angina after transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    withdrawal was not adequately addressed. However, another study, directly evaluated the effect of intermittent transdermal nitroglycerin on the occurrence of ischemia during patch-off hours in 72 patients who were randomized to 12 hours of transdermal nitroglycerin or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/56\">",
"     56",
"    </a>",
"    ]. After two weeks of therapy, patients crossed over to the alternative treatment. Compared to placebo, transdermal nitroglycerin significantly reduced the magnitude of ST segment depression at angina onset during exercise testing, but did not alter total angina frequency. Angina frequency and silent ischemia increased by 14 percent during patch-off hours compared to patch-on hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache and flushing are common symptoms in patients taking nitrate therapy, and hypotension can occur. Elderly patients should be warned about potential lightheadedness, especially in warm weather.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrates are contraindicated in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have taken",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      (Viagra) within 24 hours (because of the risk of severe hypotension). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=see_link\">",
"       \"Sexual activity in patients with heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with hypertrophic cardiomyopathy in whom nitrates can induce or increase outflow tract obstruction, even in those not known to have a resting gradient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"       \"Medical therapy in hypertrophic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with suspected right ventricular infarction, nitrates should be avoided, if possible, because of the increased risk of inducing hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"       \"Right ventricular myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, nitrates should be used cautiously in patients with severe aortic stenosis or volume depletion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reduced response in Asians",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the formation of nitric oxide from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is dependent upon the enzyme mitochondrial aldehyde dehydrogenase (ALDH2) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanism of action'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A polymorphism in this enzyme (ALDH2*2), which is present in 30 to 50 percent of Asians, virtually eliminates mtALDH activity and nitric oxide production [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/57\">",
"     57",
"    </a>",
"    ]. In a series of 80 patients from China who were being treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    for angina, 33 (41 percent) had at least one ALDH2*2 allele [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/57\">",
"     57",
"    </a>",
"    ]. These patients were significantly less likely to respond to nitroglycerin for relief of angina (58 versus 85 percent). The lack of response in all patients with the ALDH2*2 allele and the failure of all patients without this allele indicates that other factors are also important determinants of the efficacy of nitroglycerin. An investigator-observed flushing response to alcohol may be both highly sensitive specific for the presence of the ALDH2*2 allele [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345499396\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the following recommendations which were made in 2012 guideline on the diagnosis and management of stable ischemic heart disease from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Physicians/American",
"    </span>",
"    Association for Thoracic",
"    <span class=\"nowrap\">",
"     Surgery/Preventive",
"    </span>",
"    Cardiovascular Nurses",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and",
"    <span class=\"nowrap\">",
"     Interventions/Society",
"    </span>",
"    of Thoracic Surgeons",
"    <span class=\"nowrap\">",
"     (ACCF/AHA/ACP/AATS/PCNA/SCAI/STS)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/29/2521/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-acting nitrates should be prescribed for relief of anginal symptoms if there are contraindications from or adverse reactions to beta blockers.",
"     </li>",
"     <li>",
"      Long-acting nitrates should be added to beta blockers for relief of anginal symptoms if monotherapy with the latter is unsuccessful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or nitroglycerin spray is recommended for immediate relief of anginal episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    remains the treatment of choice for an acute anginal attack or for prophylaxis prior to activities known to exacerbate angina. Chronic nitrate therapy is used to prevent recurrent anginal episodes but must be dosed correctly in order to prevent tolerance. Allowing for a sufficient nitrate-free interval, nitrates may be given during the day or at night depending upon the patient's symptom complex:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with primarily exertional angina, nitrates are given during the day when the patient is more active.",
"     </li>",
"     <li>",
"      In patients with nocturnal angina or heart failure, therapy at night may be more beneficial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nitrates are especially useful in patients with heart failure, particularly at night in those with significant orthopnea or paroxysmal nocturnal dyspnea. In addition, patients with exertional dyspnea may benefit if nitrates are taken prior to exertion.",
"   </p>",
"   <p>",
"    There is no difference in efficacy among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    and transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    . Because of the problems with tolerance and rebound angina in the nitrate-free interval, we usually reserve chronic nitrate therapy for second line antianginal therapy. What follows are our recommendations for administering the most commonly used nitrate preparations. The use of nitrates in specific clinical settings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sublingual nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    remains the therapy of choice for acute anginal episodes and prophylactically for activities known to elicit angina such as mowing the lawn, playing tennis, or walking in cold weather. Our impression is that the prophylactic use of nitroglycerin is not sufficiently emphasized to patients.",
"   </p>",
"   <p>",
"    We give all patients with stable angina a prescription for sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (tablets or spray, depending upon patient preference). Patient education concerning proper dosing, storage, and side effects of sublingual nitroglycerin is extremely important. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Sublingual nitroglycerin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Isosorbide dinitrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper dosing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    is essential to prevent tolerance. We recommend a dosing schedule of 8 AM, 1 PM, and 6 PM, which results in a 14 hour nitrate dose-free interval. We begin with a dose of 10 mg three times daily, and advance to 40 mg three times daily as needed. Alternatively, isosorbide dinitrate can be taken twice daily at 8 AM and 4 PM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H520925589\">",
"    <span class=\"h2\">",
"     Isosorbide mononitrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of our experts prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    to dinitrate. When chosen, we prefer the sustained release preparation given its ease of use. If the twice daily preparation is chosen, we suggest eccentric dosing. (See",
"    <a class=\"local\" href=\"#H520925516\">",
"     'Isosorbide mononitrate'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Transdermal nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is a convenient way to administer nitroglycerin. The patient must remember to remove the patch for 12 to 14 hours. Since most patients have angina with activity, we suggest that the patch be applied at 8 AM and removed at 8 PM. The occasional patient with significant nocturnal angina can be treated with a patch-on period from 8 PM to 8 AM. We begin with a dose of 0.2",
"    <span class=\"nowrap\">",
"     mg/hr;",
"    </span>",
"    the dose can be increased to 0.8",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    as needed.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/1\">",
"      Murrell, W. Nitro-glycerine as a remedy for angina pectoris. Lancet 1879; 1:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/2\">",
"      Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998; 338:520.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/4\">",
"      Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J 1985; 110:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/5\">",
"      Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002; 99:8306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/6\">",
"      Aerts A, Dendale P, Strobel G, Block P. Sublingual nitrates during head-up tilt testing for the diagnosis of vasovagal syncope. Am Heart J 1997; 133:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/7\">",
"      Brown BG, Bolson E, Petersen RB, et al. The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response. Circulation 1981; 64:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/8\">",
"      Berglund H, Luo H, Nishioka T, et al. Preserved vasodilatory response to nitroglycerin in saphenous vein bypass grafts. Circulation 1996; 94:2871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/9\">",
"      Ginsburg R, Lamb IH, Schroeder JS, et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982; 103:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/10\">",
"      Bache RJ, Ball RM, Cobb FR, et al. Effects of nitroglycerin on transmural myocardial blood flow in the unanesthetized dog. J Clin Invest 1975; 55:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/11\">",
"      Cohen MV, Downey JM, Sonnenblick EH, Kirk ES. The effects of nitroglycerin on coronary collaterals and myocardial contractility. J Clin Invest 1973; 52:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/12\">",
"      Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/13\">",
"      Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol 1992; 70:18B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/14\">",
"      Lacoste LL, Th&eacute;roux P, Lid&oacute;n RM, et al. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol 1994; 73:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/15\">",
"      Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000; 102:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/16\">",
"      Mangione NJ, Glasser SP. Phenomenon of nitrate tolerance. Am Heart J 1994; 128:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/17\">",
"      Laursen JB, M&uuml;lsch A, Boesgaard S, et al. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation 1996; 94:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/18\">",
"      Ohashi Y, Kawashima S, Hirata Ki, et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998; 102:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/19\">",
"      Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 1998; 31:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/20\">",
"      Parker JO, Parker JD. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am J Cardiol 1992; 70:93B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/21\">",
"      Caramori PR, Adelman AG, Azevedo ER, et al. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998; 32:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/22\">",
"      M&uuml;nzel T, Holtz J, M&uuml;lsch A, et al. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N-acetylcysteine in vivo, but tolerance-independent interactions exist. Circulation 1989; 79:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/23\">",
"      H&eacute;bert D, Lam JY. Nitroglycerin rebound associated with vascular, rather than platelet, hypersensitivity. J Am Coll Cardiol 2000; 36:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/24\">",
"      Azevedo ER, Schofield AM, Kelly S, Parker JD. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol 2001; 37:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/25\">",
"      Freedman SB, Daxini BV, Noyce D, Kelly DT. Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period. J Am Coll Cardiol 1995; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/26\">",
"      Parker JD, Parker AB, Farrell B, Parker JO. Intermittent transdermal nitroglycerin therapy. Decreased anginal threshold during the nitrate-free interval. Circulation 1995; 91:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/27\">",
"      Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Minitran Efficacy Study Group. Circulation 1995; 91:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/28\">",
"      Thadani U, Maranda CR, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994; 120:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/29\">",
"      Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001; 104:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/30\">",
"      Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 2002; 39:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/31\">",
"      Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1995; 26:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/32\">",
"      Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997; 96:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/33\">",
"      Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. J Am Coll Cardiol 1998; 31:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/34\">",
"      Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of ascorbate on the preventive effect of nitrate tolerance in patients with congestive heart failure. Circulation 1998; 97:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/35\">",
"      Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol 1998; 32:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/36\">",
"      Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol 1998; 32:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/37\">",
"      Katz RJ, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotension converting enzyme inhibitors. Circulation 1991; 83:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/38\">",
"      Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 66:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/39\">",
"      Cotter G, Metzkor-Cotter E, Kaluski E, et al. Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris. Am J Cardiol 1998; 82:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/40\">",
"      Parker JD, Parker AB, Farrell B, Parker JO. Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina. Circulation 1996; 93:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/41\">",
"      Lee G, Mason DT, De Maria AN. Effects of long-term oral administration of isosorbide dinitrate on the antianginal response to nitroglycerin. Absence of nitrate cross-tolerance and self-tolerance shown by exercise testing. Am J Cardiol 1978; 41:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/42\">",
"      Leslie WS, Urie A, Hooper J, Morrison CE. Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care. Heart 2000; 84:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/43\">",
"      Simon AB, Feinleib M, Thompson HK Jr. Components of delay in the pre-hospital phase of acute myocardial infarction. Am J Cardiol 1972; 30:476.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/46\">",
"      Rasler FE. Ineffectiveness of sublingual nitroglycerin in patients with dry mucous membranes. N Engl J Med 1986; 314:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/47\">",
"      Bailie GR, Kay EA. Patients' knowledge of sublingual glyceryl trinitrate. BMJ 1988; 297:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/48\">",
"      NitroMist nitroglycerin spray for angina. Med Lett Drugs Ther 2011; 53:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/49\">",
"      Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol 1982; 49:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/50\">",
"      Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987; 316:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/51\">",
"      Bassan MM. The daylong pattern of the antianginal effect of long-term three times daily administered isosorbide dinitrate. J Am Coll Cardiol 1990; 16:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/52\">",
"      Parker JO. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993; 72:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/53\">",
"      Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993; 72:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/54\">",
"      Parker JO, Fung HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984; 54:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/55\">",
"      Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Am J Cardiol 1991; 68:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/56\">",
"      Pepine CJ, Lopez LM, Bell DM, et al. Effects of intermittent transdermal nitroglycerin on occurrence of ischemia after patch removal: results of the second transdermal intermittent dosing evaluation study (TIDES-II). J Am Coll Cardiol 1997; 30:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/57\">",
"      Li Y, Zhang D, Jin W, et al. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest 2006; 116:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/58\">",
"      Wall TL, Thomasson HR, Ehlers CL. Investigator-observed alcohol-induced flushing but not self-report of flushing is a valid predictor of ALDH2 genotype. J Stud Alcohol 1996; 57:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/59\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/29/2521/abstract/60\">",
"      Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1549 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2521=[""].join("\n");
var outline_f2_29_2521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effect on systemic hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect on coronary hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antiplatelet and antithrombotic properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NITRATE TOLERANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanisms of tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMMONLY USED NITRATE PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sublingual nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nitroglycerin spray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Isosorbide dinitrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H520925516\">",
"      Isosorbide mononitrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transdermal nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reduced response in Asians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H345499396\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sublingual nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Isosorbide dinitrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H520925589\">",
"      Isosorbide mononitrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Transdermal nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1549\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1549|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/21/10590\" title=\"figure 1\">",
"      Nitrate induced vasodilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/16/37134\" title=\"figure 2\">",
"      Tolerance to ISDN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/44/26317\" title=\"figure 3\">",
"      Limited efficacy of TID ISDN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/59/7102\" title=\"figure 4\">",
"      Intermittent transdermal NTG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24566?source=related_link\">",
"      Nitrates in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_29_2522="Hypoglossal palsy ICA dissection";
var content_f2_29_2522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F86467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F86467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Isolated hypoglossal nerve palsy due to internal carotid artery dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The patient's tongue deviated to the left.",
"    <br/>",
"    (B) T1-weighted MRI demonstrates narrowing of the lumen and intramural hematoma in the left internal carotid artery.",
"    <br/>",
"    (C) True fast MRI with steady-state precession reveals the anatomic juxtaposition of the hypoglossal nerve (arrowhead) and the dissected internal carotid artery (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Okunomiya T, Kageyama T, Suenaga T. Teaching NeuroImages: Isolated hypoglossal nerve palsy due to internal carotid artery dissection. Neurology 2012; 79:e37. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2522=[""].join("\n");
var outline_f2_29_2522=null;
var title_f2_29_2523="TEE factors for embolism AF";
var content_f2_29_2523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indicators of thromboembolic risk on transesophageal echocardiography in patients with atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Left atrial appendage size and function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left atrial size and function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous echo contrast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left atrial or atrial appendage thrombus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraatrial septal aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patent foramen ovale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aortic atherosclerosis with plaque in ascending aorta",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2523=[""].join("\n");
var outline_f2_29_2523=null;
var title_f2_29_2524="Probability of MI in chest pain";
var content_f2_29_2524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features that increase the probability of myocardial infarction in patients presenting with new chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Likelihood ratio (95 percent",
"CI)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain in chest or left arm",
"       </td>",
"       <td>",
"        2.7*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Chest pain radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right shoulder",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.9 (1.4-6.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Left arm",
"       </td>",
"       <td class=\"sublist_other\">",
"        2.3 (1.7-3.1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Both left",
"and right arm",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.1 (3.6-14.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest pain most important symptom",
"       </td>",
"       <td>",
"        2.0*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of myocardial infarction",
"       </td>",
"       <td>",
"        1.5-3.0&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea or vomiting",
"       </td>",
"       <td>",
"        1.9 (1.7-2.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diaphoresis",
"       </td>",
"       <td>",
"        2.0 (1.9-2.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Third heart sound on auscultation",
"       </td>",
"       <td>",
"        3.2 (1.6-6.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension (systolic BP &le;80 mmHg)",
"       </td>",
"       <td>",
"        3.1 (1.8-5.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary crackles on auscultation",
"       </td>",
"       <td>",
"        2.1 (1.4-3.1)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Data not available to calculate confidence interval (CI).",
"     <br>",
"      &bull; In heterogeneous studies the likelihood ratios are reported as ranges.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Panju, AA, Hemmelgarn, BR, Guyatt, GH, Simel, DL, JAMA 1998; 280:1256.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2524=[""].join("\n");
var outline_f2_29_2524=null;
var title_f2_29_2525="Reporting elements for ER and PR immunohistochemistry assays";
var content_f2_29_2525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reporting elements for ER and PR immunohistochemistry assays",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Patient identification information",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Physician identification",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Date of service",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Specimen site and type",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"color: #008000;\">",
"         Specimen identification (case and block number)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fixative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold ischemia time (time between removal and fixation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of fixation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Staining method utilized:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary antibody and vendor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Assay details and other reagents/vendors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        References supporting validation of assay (note: most commonly, these will be published studies performed by others that the testing laboratory is emulating)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Status of FDA approval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Controls (high protein expression, low-level protein expression, negative protein expression, internal elements or from normal breast tissue included with sample)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adequacy of sample for evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <span style=\"color: #008000;\">",
"         Results:",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span style=\"color: #008000;\">",
"         Percentage of invasive tumor cells exhibiting nuclear staining",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span style=\"color: #008000;\">",
"         Intensity of staining: Strong, medium, weak",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <span style=\"color: #008000;\">",
"         Interpretation:",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        -",
"        <span style=\"color: #008000;\">",
"         Positive (for ER or PR receptor protein expression), negative (for ER or PR protein expression), uninterpretable",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        -",
"        <span style=\"color: #008000;\">",
"         Internal and external controls (positive, negative, not present)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        -",
"        <span style=\"color: #008000;\">",
"         Standard assay conditions met/not met (including cold ischemic time and fixation parameters)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        -",
"        <span style=\"color: #008000;\">",
"         Optional score and scoring system",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        - Comment: Should explain reason for uninterpretable result and or any other unusual conditions, if applicable. May report on status of any DCIS staining in the sample. Should also provide correlation with histologic type of the tumor. May provide information about laboratory accreditation status.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Report should contain the elements in",
"    <span style=\"color:#008000\">",
"     <strong>",
"      green",
"     </strong>",
"    </span>",
"    as a minimum. Other information must be available in the laboratory for review or appear on the patient accession slip.",
"    <div class=\"footnotes\">",
"     ER: estrogen receptor; PR: progesterone receptor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2525=[""].join("\n");
var outline_f2_29_2525=null;
var title_f2_29_2526="Improper coaxial movement";
var content_f2_29_2526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Inappropriate coaxial movement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 124px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inappropriate coaxial movement between the bronchoscope and the forceps can push the foreign body out of the forceps cups or jaws, leading to loss of the object.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2526=[""].join("\n");
var outline_f2_29_2526=null;
var title_f2_29_2527="Oropharyngeal airways";
var content_f2_29_2527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oropharyngeal airways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_29_2527=[""].join("\n");
var outline_f2_29_2527=null;
